Publications

Healthcare & Life Sciences

European Federation of Pharmaceutical Industries and Associations

The value and cost of a Supplementary Protection Certificate extension in Europe

Healthcare & Life Sciences

Danish Association of Parallel Importers of Pharmaceuticals

The economic impact of parallel imports of pharmaceuticals – An assessment of savings in Denmark in 2025

Healthcare & Life Sciences

Takeda

The impact of plasma-derived therapies in Europe – 2026 edition

Healthcare & Life Sciences

The Pharmaceutical Research and Manufacturers of America (PhRMA)

QALY use in selected OECD countries

Healthcare & Life Sciences

European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

Economic contribution of EUCOPE’s membership and trade implications following U.S. policy measures

Healthcare & Life Sciences

European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

Competitiveness of the EU life sciences sector

Healthcare & Life Sciences

Alexion, AstraZeneca Rare Disease

Spending on orphan medicinal products across Europe: What drives it, and is it sustainable?

Healthcare & Life Sciences

Danish Guides and Scouts Association

Evaluating the societal impact of scouting

Healthcare & Life Sciences

EUCOPE

An EU Access Toolbox for Orphan Medicinal Products that enables early and equitable access

Healthcare & Life Sciences

GSK

Rotavirus vaccine – Technical and economic arguments regarding implementation of rotavirus vaccination in the Danish immunisation programme

Healthcare & Life Sciences

US Hereditary Angioedema Association (HAEA)

Development and validation of a US quality-of-life instrument for hereditary angioedema due to C1 inhibitor deficiency

Healthcare & Life Sciences

PhRMA

Regulatory data protection for pharmaceuticals – How implementing RDP in China will benefit society, industry and the Chinese economy

Healthcare & Life Sciences

European Federation of Pharmaceutical Industries and Associations (EFPIA)

Cost and value of regulatory data protection

Healthcare & Life Sciences

EURORDIS, Alexion AstraZeneca Rare Disease, Takeda, Orphanet

Enabling, not rewarding: How to design a high unmet medical needs category to drive, not deter, innovation in orphan medicinal products

Healthcare & Life Sciences

Novartis Healthcare A/S

Real-world evidence on the economic implications of CGRP inhibitors as preventive treatment of migraine in Denmark

Healthcare & Life Sciences

OD Expert Group

The value and cost of a Supplementary Protection Certificate extension in Europe

The economic impact of parallel imports of pharmaceuticals – An assessment of savings in Denmark in 2025

The impact of plasma-derived therapies in Europe – 2026 edition

QALY use in selected OECD countries

Economic contribution of EUCOPE’s membership and trade implications following U.S. policy measures

Competitiveness of the EU life sciences sector

Spending on orphan medicinal products across Europe: What drives it, and is it sustainable?

Evaluating the societal impact of scouting

An EU Access Toolbox for Orphan Medicinal Products that enables early and equitable access

Rotavirus vaccine – Technical and economic arguments regarding implementation of rotavirus vaccination in the Danish immunisation programme

Development and validation of a US quality-of-life instrument for hereditary angioedema due to C1 inhibitor deficiency

Regulatory data protection for pharmaceuticals – How implementing RDP in China will benefit society, industry and the Chinese economy

Cost and value of regulatory data protection

Enabling, not rewarding: How to design a high unmet medical needs category to drive, not deter, innovation in orphan medicinal products

Real-world evidence on the economic implications of CGRP inhibitors as preventive treatment of migraine in Denmark

European Union health technology assessment fit for rare diseases